The enactment of SB33 would significantly impact state health care laws by allowing eligible patients to bypass traditional treatment protocols when facing terminal conditions. It establishes clear definitions for eligible patients and treatments, promotes the right of these patients to make informed decisions, and enables manufacturers to provide personalized treatments without bearing liability for adverse outcomes, provided they adhere to good faith practices. This bill promotes innovation in treatment options and empowers patients to take control of their health decisions.
Summary
Senate Bill 33, titled the 'Right to Try Individualized Treatments Act,' seeks to provide patients with life-threatening or severely debilitating diseases the opportunity to access individualized investigational treatments. This legislation is designed for those who have explored all other FDA-approved treatment options and have received a physician's recommendation based on an analysis of their genetic profile. By creating a legal pathway for these patients, the bill aims to facilitate potentially life-saving treatments that are otherwise unavailable through standard medical channels.
Contention
However, the bill is not without controversy. Some legislators and health care advocates have expressed concerns regarding the lack of protections for patients, particularly regarding informed consent and the liability implications for manufacturers. Critics argue that while patients should be allowed access to experimental treatments, the potential risks and liabilities associated with individualized investigational treatments need to be carefully regulated to prevent exploitation and ensure patient safety. Ensuring that patients understand the risks involved in such treatments—including financial liabilities and the potential for unanticipated side effects—remains a point of contention in the discussions surrounding the bill.
Health: other; individualized investigational treatment for certain patients suffering from a life-threatening or severely debilitating illness; provide for. Amends title & secs. 1, 2, 3, 4, 5, 6 & 7 of 2014 PA 345 (MCL 333.26451 et seq.) & adds sec. 2a.
To Create The Right To Try Individualized Investigational Treatment Act; And To Ensure That Patients Have Access To Individualized Investigational Treatment.